Stock Market Reviews

Read and share opinions on SPRC (SciSparc Ltd.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
  Dec 30, 2025
• Neurothera Labs Granted Patent by Israeli Patent Office for Its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
  Dec 30, 2025
• Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
  Dec 2, 2025
• SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
  Dec 2, 2025
• SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio
  Dec 1, 2025
• SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems
  Nov 26, 2025
• SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
  Nov 20, 2025
• Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
  Nov 19, 2025
• SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
  Oct 24, 2025
• SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
  Oct 23, 2025
• SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
  Oct 23, 2025
• SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio
  Oct 15, 2025
• SciSparc And AutoMax Call Off Merger
  Oct 6, 2025
• SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors
  Oct 6, 2025
• SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
  Sep 29, 2025

SPRC News

• IM Cannabis Appoints Asi Levi as Chief Financial Officer
  IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced, further to its press release dated October 29, 2025, the appointment of Asi Levi, CPA, as the Company's Chief Financial Officer ("CFO"), effective immediately, to replace Uri Birenberg.
  Dec 12, 2025
• Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
  VANCOUVER, BC - December 2, 2025 (NEWMEDIAWIRE) - Neurothera Labs Inc. (TSXV: NTLX) ("Neurothera" or the "Company"), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced that it has entered...
  Dec 2, 2025
• SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
  TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a non-binding term sheet (the “Term Sheet”) with an Israeli-based pioneering quantum computing bio data company focuse
  Dec 2, 2025
• SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio
  TEL AVIV, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., recently announced the signing of a binding term sheet to acquire treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. ("Xylo”). The MUSE™ system
  Dec 1, 2025
• SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems
  TEL AVIV, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., today announced the signing of a binding term sheet to acquire a treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. ("Xylo”). The MUSE™ system
  Nov 26, 2025
• SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
  TEL AVIV, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine Inc. by filing an Israeli patent application for an innovative combination
  Nov 20, 2025
• Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
  VANCOUVER, BC - November 19, 2025 (NEWMEDIAWIRE) - Neurothera Labs Inc. (TSXV: NTLX) ("Neurothera" or the "Company"), a clinical-stage biotech company and a wholly-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced that Clearmind Medic...
  Nov 19, 2025
• Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
  Vancouver, Canada, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of an Israeli patent application for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing
  Nov 17, 2025
• N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers
  Neve Yarak, Israel, Oct. 30, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced the closing of the merger with MitoCareX Bio Ltd. ("MitoCareX"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial SLC25 protein family. MitoCareX is f
  Oct 30, 2025
• SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
  TEL AVIV, Israel, Oct. 24, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the closing of the transactions under the asset and share purchase agreement by and among the Company, Miza III Ventures Inc. and SciSparc Nutraceuticals Inc. (the “Agreement”). Pursuant to the Agreement, SciSparc rec
  Oct 24, 2025
• SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
  TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, recently announced that on September 16, 2025 the board of directors resolved to initiate the launch of an innovative initiative to advance 3D protein modeling using quantum computing technology (the “Initiative”). This new program aims to transfo
  Oct 23, 2025
• SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
  TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the closing of the sale to N2OFF, Inc. (Nasdaq: NITO) (“N2OFF”) of SciSparc’s majority owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”). MitoCareX is focusing on the development of novel therapies for hard-to-treat cancers by tar
  Oct 23, 2025
• SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio
  According to the agreement, SciSparc’s pharmaceuticals assets and equity stake in SciSparc Nutraceuticals Inc. are valued at approximately US$11.6 million TEL AVIV, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that on October 9, 2025, the Company entered into a definitive
  Oct 15, 2025
• SciSparc And AutoMax Call Off Merger
  SciSparc Ltd. (NASDAQ:SPRC) said Monday it has entered a framework agreement with AutoMax Motors Ltd. to mutually terminate their planned merger, officially ending a deal that would have expanded the company into Israel’s automotive market. The Tel Aviv-based drug developer stated that the October 6, 2025, agreement outlines repayment terms for prior loans extended to AutoMax and supersedes the earlier merger pact. Both companies agreed to end all merger-related obligations and settle financial
  Oct 6, 2025
• SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors
  TEL AVIV, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the entry into a framework agreement for mutual termination of merger, dated October 6, 2025, by and between the Company, AutoMax Motors Ltd. ("AutoMax") and SciSparc Merger Sub Ltd. This agreement outlines key steps to resolve pri
  Oct 6, 2025
• SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
  TEL AVIV, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that on September 25, 2025, the stockholders of N2OFF, Inc. (NASDAQ: NITO) (“N2OFF”) voted on and approved, among other things, the proposed acquisition of SciSparc’s majority owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”). Th
  Sep 29, 2025
• Top Midday Gainers
  PepGen (PEPG) shares rose Thursday after the company said late Wednesday it achieved the highest mea
  Sep 25, 2025
• N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
  Neve Yarak, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, announced today that a special meeting of stockholders held on September 25, 2025, its stockholders voted on and approved, among others, the proposed acquisition of MitoCareX Bio Ltd. ("MitoCareX"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range
  Sep 25, 2025
• SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery
  TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the board of directors resolved to initiate the launch of an innovative initiative to advance 3D protein modeling using quantum computing technology (the “Initiative”). This new program aims to transform drug discovery by pot
  Sep 25, 2025
• Wall Street Set to Open Little Changed Wednesday as Investors Anticipate Fed Rate Cut
  US stocks appear set to open relatively unchanged in Wednesday's trading session as investors look a
  Sep 17, 2025
• SciSparc: AutoMax’s Shareholders Approve Merger with SciSparc
  TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that AutoMax Motors Ltd. ("AutoMax"), a leading parallel vehicle importer in Israel, convened today its special general meetings, at which, among others, AutoMax’s shareholders voted on and approved the proposed merger with SciSpar
  Aug 28, 2025
• SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel
  TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that at adjourned special general meeting of shareholders held on August 26, 2025, its shareholders voted on and approved, among others, the proposed merger with AutoMax Motors Ltd. ("AutoMax"), a leading parallel vehicle importer
  Aug 28, 2025
• SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
  TEL AVIV, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the publication of an international patent application under the Patent Cooperation Treaty (PCT). The patent application publ
  Aug 7, 2025
• Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
  Vancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc"), a speci
  Aug 7, 2025
• Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
  Vancouver, Canada, July 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international patent application under the Patent Cooperation Treaty (PCT). The application covers its innovative combination therapy of MEAI (5-methoxy-2-aminoindane an
  Jul 30, 2025
• SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC
  TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announces additional progress in connection with the proposed merger with AutoMax Motors Ltd., a leading vehicles importer and the exclusive importer of Anhui Jianghuai Automobile Group Corp., Ltd.-manufactured electric vehicles in Israel (“AutoMa
  Jul 30, 2025
• SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
  TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the filing of a new international patent application under the Patent Cooperation Treaty. The application covers its innovati
  Jul 30, 2025

SPRC Reviews

• ProfitVandal

  Dec 30, 2025

  $SPRC A spark that barely ignites any interest.

  Sell

• TradeHex

  Dec 30, 2025

  $SPRC Operating in a niche market, this company has potential for considerable growth through innovative product offerings. Its efforts to penetrate new territories could lead to heightened market visibility.

  Buy

• TheLongPlay

  Dec 29, 2025

  $SPRC Feeling a little shaky, the vibe ain’t right for now!

  Sell

• ShortSniper

  Dec 28, 2025

  $SPRC This company’s potential is as elusive as its name.

  Sell

• TradePhantom

  Dec 27, 2025

  $SPRC This one seems to be floating in the shallow end.

  Sell

• ProfitVandal

  Dec 27, 2025

  $SPRC Investing here feels like betting on a one-legged horse.

  Sell

• TradePredator

  Dec 26, 2025

  $SPRC Just another overhyped dream in a sea of mediocrity.

  Sell

• CashCombo

  Dec 26, 2025

  $SPRC This company is like that friend who keeps bringing snacks to the party—always delivering something tasty for everyone to enjoy!

  Buy

• StockSpecter

  Dec 26, 2025

  $SPRC This one’s more of a science experiment than a company.

  Sell

• EquityPulse

  Dec 25, 2025

  $SPRC With innovation at a fever pitch, this company has to stay ahead of pharmaceutical trends! Their next move could either catapult them or send them spiraling!

  Buy

• AlphaRift

  Dec 24, 2025

  $SPRC This innovative biotech company is making strides in drug development, showcasing potential breakthroughs that could significantly enhance treatment options in the healthcare sector.

  Buy

• WallStreetRogue

  Dec 24, 2025

  $SPRC There’s something about this stock that keeps you on edge! Just when you think you’ve figured it out, a twist sends your heart racing. Can you handle the suspense?

  Sell

• ShortSurge

  Dec 24, 2025

  $SPRC As a player in the biotech arena, there are compelling developments on the horizon that could enhance its market position and investor interest in the coming months.

  Buy

• ShortCircuit

  Dec 24, 2025

  $SPRC Their science seems more like fiction at this point.

  Sell

• ChartPhantom

  Dec 23, 2025

  $SPRC SciSparc is like that one friend who always has the weirdest science facts—never boring, but also kind of a gamble!

  Sell

• FinTechNomad

  Dec 22, 2025

  $SPRC The excitement around this biotech firm is palpable, but the specter of clinical trials hangs over them like a dark cloud. One setback could lead to a freefall, and investors are anxiously watching every move.

  Sell

• MarginMyth

  Dec 22, 2025

  $SPRC A spark in a dull industry isn't enough to light the way.

  Sell

• FUDCrusher

  Dec 22, 2025

  $SPRC They’re in the lab mixin' it up, but can they cook up the magic?

  Sell

• TradeSaber

  Dec 21, 2025

  $SPRC Got a spark that might just ignite a fire!

  Buy

• RiskRaider

  Dec 20, 2025

  $SPRC It's like waiting for paint to dry; zero excitement here.

  Sell

• BuyLowBro

  Dec 20, 2025

  $SPRC This company is like that friend who always has a wild idea but somehow makes it work. Just hope they don’t try to sell me moon rocks!

  Buy

• TradePulse

  Dec 20, 2025

  $SPRC In the race for innovative therapies, the competition is fierce and the clock is ticking. Are they on the brink of a breakthrough or just another false start? The uncertainty is palpable!

  Buy

• MarginMarauder

  Dec 20, 2025

  $SPRC If this stock were a snack, it’d be a spicy chip—unexpectedly fiery and definitely keeping things interesting!

  Buy

• ProfitVortex

  Dec 20, 2025

  $SPRC This stock is like a science experiment – sometimes it blows up, but when it works, it’s pure genius!

  Buy

• BullRaid

  Dec 19, 2025

  $SPRC Expecting sparks? More like a fizzling dud.

  Sell

• ShortSurge

  Dec 19, 2025

  $SPRC With a unique approach to therapeutic solutions, this company is carving out a niche in the biotech sector. Its focus on cutting-edge research and development may lead to significant advancements in treatment options, making it a noteworthy player.

  Buy

• MarketReaper

  Dec 19, 2025

  $SPRC This one feels like the awkward cousin at family gatherings—sometimes they're great, but other times you avoid them like the plague.

  Sell

• TradeBlitz

  Dec 17, 2025

  $SPRC If science fair projects were stocks, this one would definitely have the coolest volcano experiment!

  Buy

• LiquidityLord

  Dec 16, 2025

  $SPRC This firm is actively engaged in pioneering research, which has the potential to unlock significant advancements in its field. The dedication to developing transformative solutions may position it as a key player going forward.

  Buy

• TradeProtocol

  Dec 16, 2025

  $SPRC With a name like SciSparc, I’m half expecting them to develop a pizza that delivers itself through space!

  Buy

• CashCraze

  Dec 15, 2025

  $SPRC Positioned within the biotech industry, this company is exploring cutting-edge research that could lead to significant advancements. Their focus on innovative therapies underscores a strong commitment to addressing critical health challenges.

  Buy

• BullishBerserker

  Dec 15, 2025

  $SPRC Trend weakening with heavy downside risk.

  Sell

• AlphaWave

  Dec 13, 2025

  $SPRC Amidst the chaos of biotech, this one feels like a high-stakes gamble. Every move could either make or break its reputation. Can it handle the heat?

  Sell

• GainsGoblin

  Dec 13, 2025

  $SPRC This one's got some spicy moves in biotech, stay tuned!

  Buy

• CapitalCrusher

  Dec 12, 2025

  $SPRC This biotech firm is like that kid in class who knows all the answers—smart, but maybe a little too quiet. Time to shine!

  Buy

• DividendVandal

  Dec 12, 2025

  $SPRC As an innovator in the biotech field, this entity is pushing the boundaries of research and development. Its pipeline of projects demonstrates a strong commitment to advancing healthcare solutions.

  Buy

• BullishBard

  Dec 12, 2025

  $SPRC Momentum turning sharply upward.

  Buy

• ShortKingston

  Dec 12, 2025

  $SPRC Imagine this stock as the underdog in a classic movie—everyone loves rooting for it, no matter the odds!

  Buy

• ChartSaber

  Dec 12, 2025

  $SPRC Bearish dominance undeniable.

  Sell

• BearBreaker

  Dec 12, 2025

  $SPRC The future looks hazy, and not in a good way.

  Sell

• StonkPhantom

  Dec 12, 2025

  $SPRC Navigating the biotech landscape is a tricky endeavor, full of highs and lows. Will this company find a breakthrough or stumble through the rough patches?

  Sell

• MoonBagz

  Dec 11, 2025

  $SPRC Unfavorable macro sentiment.

  Sell

• TrendStalker

  Dec 11, 2025

  $SPRC Heavy bearish exhaustion signal.

  Sell

• QuantAssault

  Dec 11, 2025

  $SPRC Market leaning heavily bullish here.

  Buy

• OptionOutlaw

  Dec 11, 2025

  $SPRC Downtrend gaining traction.

  Sell

• GammaSlayer

  Dec 11, 2025

  $SPRC Market confidence clearly bullish.

  Buy

• BullishCraze

  Dec 11, 2025

  $SPRC Too many red flags in chart.

  Sell

• LiquidLegend

  Dec 10, 2025

  $SPRC If sparks flew every time a great idea was born, this company would need a fire extinguisher for all the brilliance!

  Buy

• FinTechNomad

  Dec 10, 2025

  $SPRC This company is an enigma! It could either soar to new heights or crash spectacularly. The tension in the air is thick—how will it pan out?

  Buy

• CapitalFrame

  Dec 9, 2025

  $SPRC Supply zones rejecting price sharply.

  Sell

• BullishBerserker

  Dec 8, 2025

  $SPRC With the market’s unpredictable appetite for biotech, this firm is in a nerve-wracking position. Will their innovations be the next big thing or just another missed opportunity?

  Sell

• BullishBard

  Dec 8, 2025

  $SPRC This stock is like that quirky friend who always has the most interesting stories at parties. You just can't look away!

  Buy

• MarketReaper

  Dec 8, 2025

  $SPRC This company is like that friend who always brings snacks to the party – everyone’s happy when they show up!

  Buy

• PaperHandsGone

  Dec 7, 2025

  $SPRC This one's got some serious vibes, might just blow up soon, ya know?

  Buy

• BullishBard

  Dec 7, 2025

  $SPRC This stock is like a surprise party – you never know what to expect, but the thrill is what keeps you coming back for more!

  Sell

• CapitalFrame

  Dec 7, 2025

  $SPRC With a focus on pioneering scientific advancements, this company is positioned within a niche market that has significant growth potential. Their ongoing research initiatives are likely to yield valuable breakthroughs.

  Buy

• AlphaVandal

  Dec 6, 2025

  $SPRC Looks like a gamble that rarely pays off.

  Sell

• VolatilityViper

  Dec 6, 2025

  $SPRC Support levels cracking one by one.

  Sell

• TheChartCode

  Dec 5, 2025

  $SPRC This company's like that kid in class who always asks the teacher for extra credit. Just when you think it's done, it surprises you with more potential!

  Buy

• OptionOverlord

  Dec 5, 2025

  $SPRC SciSparc? Sounds like the name of an alien spaceship! Hope they’re not trying to take over the world; that’s kind of a buzzkill.

  Sell

• TendieTitan

  Dec 5, 2025

  $SPRC This company's got the spark to light up your investment timeline—just don’t get burned!

  Buy

• TheStockKnight

  Dec 4, 2025

  $SPRC A classic case of 'what were they thinking?'

  Sell

• HODLzilla

  Dec 4, 2025

  $SPRC This one’s a wild card, might surprise ya!

  Buy

• HODLWarrior

  Dec 4, 2025

  $SPRC Bearish shockwave forming.

  Sell

• BearBreaker

  Dec 3, 2025

  $SPRC Investing in this feels like chasing shadows.

  Sell

• GainVector

  Dec 2, 2025

  $SPRC Operating at the intersection of biotech and technology, this company is focused on groundbreaking therapies in neuroscience. Its innovative research approach could lead to significant advancements in treatment options.

  Buy

• MarginMythic

  Dec 2, 2025

  $SPRC The race for breakthroughs in the biotech field is fierce. Will this company be the underdog that surprises everyone, or will it falter under the pressure?

  Buy

• LiquidityLord

  Dec 1, 2025

  $SPRC The company focuses on pioneering therapeutic solutions that address significant unmet needs in the medical field, showcasing a commitment to innovation and patient care.

  Buy

• MarketReaper

  Dec 1, 2025

  $SPRC This stock shines like a glitter unicorn at a birthday party—hard to ignore and totally magical!

  Buy

• ShortCircuit

  Dec 1, 2025

  $SPRC This is as exciting as watching paint dry.

  Sell

• AlphaHawk

  Dec 1, 2025

  $SPRC This crew's cooking up some wild innovations, stay tuned!

  Buy

• AlgoAce

  Nov 30, 2025

  $SPRC This stock’s like a science experiment gone wild—sometimes it’s a total explosion, but hey, it’s all about discovery!

  Sell

• BearHunter

  Nov 30, 2025

  $SPRC Like a science fair project gone right, this stock brings the ‘wow’ factor—just don't mix it up with vinegar and baking soda!

  Buy

• LiquidLegend

  Nov 30, 2025

  $SPRC They’re kinda like a science experiment—could explode with success or, you know, fizzle out. Keep your goggles on!

  Sell

• CashKiller

  Nov 30, 2025

  $SPRC More like Sci-Flop; prepare for a long wait with no reward.

  Sell

• TradeMatrix

  Nov 30, 2025

  $SPRC In the biotech arena, breakthroughs are everything! Will this company hit the jackpot with their next big project or spiral into obscurity? Excitement and anxiety are through the roof!

  Buy

• AlphaRift

  Nov 30, 2025

  $SPRC This enterprise is exploring cutting-edge solutions in the biotech field, demonstrating a strategic focus on research that could lead to significant breakthroughs in the near future.

  Buy

• MarginLogic

  Nov 29, 2025

  $SPRC In the biopharmaceutical sector, this company is focusing on groundbreaking therapies that target unmet medical needs. Their research and development efforts might hold significant promise for future growth.

  Buy

• BullRunBoi

  Nov 29, 2025

  $SPRC They’re sparkin' interest, but gotta see if they light up or fizzle out, ya dig?

  Sell

• TheStockKnight

  Nov 28, 2025

  $SPRC Another day, another overhyped biotech with no promise.

  Sell

• MarginMeme

  Nov 28, 2025

  $SPRC Feeling kinda sketchy, might wanna think twice on this one.

  Sell

• ShortSqueezeX

  Nov 27, 2025

  $SPRC This company is sparking more interest than a cat video on a Friday night! Can’t look away!

  Buy

• MarketPulseX

  Nov 27, 2025

  $SPRC The company is exploring innovative solutions within its niche, showcasing a proactive approach to adaptation in an evolving industry landscape. Exciting developments could enhance its market position.

  Buy

• MarketWolf

  Nov 27, 2025

  $SPRC Innovation? Sure! But can they keep up with the competition? The pressure to deliver groundbreaking results can be suffocating, and any hiccup could lead to a nosedive.

  Sell

• LiquidityLord

  Nov 27, 2025

  $SPRC With a focus on biotech innovation, this company is exploring unique therapeutic avenues that could address unmet medical needs. Their ongoing research efforts hold potential for substantial breakthroughs in the industry.

  Buy

• WallStreetWolf

  Nov 26, 2025

  $SPRC Bringing a spark to science! If only my chemistry class was this lit!

  Sell

• CodeAndCapital

  Nov 25, 2025

  $SPRC Science is cool, but make it sparkly! This stock's got the energy we need for a science fiction movie!

  Sell

• BearBreaker

  Nov 25, 2025

  $SPRC Innovative? More like uninspired and irrelevant.

  Sell

• MarketRender

  Nov 25, 2025

  $SPRC The buzz is mixed, and the future seems murky. One minute it's in the spotlight, the next it’s out of favor—this could lead to a wild ride ahead. Can it regain stability?

  Sell

• TheLongPlay

  Nov 24, 2025

  $SPRC Might be sleeping now, but watch it wake up, ya dig?

  Buy

• MarketMarauder

  Nov 24, 2025

  $SPRC Chasing sparks but only finding duds.

  Sell

• TradeBlaze

  Nov 24, 2025

  $SPRC Engaging in innovative research, this biotechnology firm is exploring novel approaches that could lead to significant breakthroughs in treatment options, which may enhance its standing in the market.

  Buy

• FiscalBinary

  Nov 23, 2025

  $SPRC Every headline sends shockwaves through this stock! It’s a wild ride of excitement and uncertainty, leaving you breathless. One moment it’s hot, the next it’s ice cold!

  Sell

• TrendStalker

  Nov 23, 2025

  $SPRC Just another flashy name with no substance.

  Sell

• OptionOutlaw

  Nov 22, 2025

  $SPRC Good luck finding value in this mess.

  Sell

• FOMOKing

  Nov 22, 2025

  $SPRC This one’s got potential to pop, keep an eye on it, fam!

  Buy

• ProfitVandal

  Nov 21, 2025

  $SPRC Just another face in the crowd of mediocrity. How inspiring.

  Sell

• WallStreetRogue

  Nov 21, 2025

  $SPRC This company is teetering on the edge of breakthrough and burnout! The potential is palpable, but the pressure is intense. Will they rise to the occasion or crumble under expectations? It's a thrilling ride!

  Buy

• TheQuantEdge

  Nov 21, 2025

  $SPRC With a lot riding on its next moves, the pressure is mounting. Will it deliver or will investors feel the burn of missed opportunities?

  Sell

• RiskRanger

  Nov 21, 2025

  $SPRC Sci-fi meets finance! Investing here feels like betting on the next big blockbuster, fingers crossed for a sequel!

  Buy

• BearEater

  Nov 20, 2025

  $SPRC With its unique approach to biotechnology, this firm is carving out a niche that could prove advantageous as healthcare demands continue to rise. Their recent developments indicate a commitment to pushing boundaries in their field.

  Buy

• MarginLogic

  Nov 20, 2025

  $SPRC This innovative company is positioned at the intersection of technology and healthcare, offering unique solutions that address significant market needs. Its strong growth potential reflects a commitment to advancing industry standards and improving quality of life.

  Buy

• ShortRaid

  Nov 20, 2025

  $SPRC With a focus on developing innovative therapeutics, this company aims to address unmet medical needs. Their research initiatives could pave the way for groundbreaking advancements in healthcare.

  Buy

• YieldMyth

  Nov 20, 2025

  $SPRC Aiming for the stars, might just hit that sweet spot soon!

  Buy

• CodeAndCapital

  Nov 19, 2025

  $SPRC This stock is like a science project—lots of potential, but also a wild card! 🧬

  Sell

• LazyQuant

  Nov 18, 2025

  $SPRC Like a science project gone wild, it has potential for greatness, but you might get stuck cleaning up the mess!

  Sell

• MemeInvestor

  Nov 17, 2025

  $SPRC If innovation were a dance, this company is doing the cha-cha while everyone else is still learning the macarena!

  Buy

• FiscalEngine

  Nov 16, 2025

  $SPRC In the biotechnology space, this company is exploring unique therapeutic avenues that could set it apart from competitors. Their innovative approaches and focus on unmet medical needs present compelling opportunities in an industry ripe for breakthrough treatments.

  Buy

• HODLzilla

  Nov 16, 2025

  $SPRC This crew's all about innovation, pushing limits and reaching new heights.

  Buy

• ChartSaber

  Nov 15, 2025

  $SPRC This one’s a wildcard, but the potential's lit, fam.

  Buy

• OptionCipher

  Nov 15, 2025

  $SPRC A wild rollercoaster of potential! It feels like every day could lead to a breakthrough or a plunge. If you're not on your toes, you might miss out on the exhilarating ride!

  Buy

• CashMeOutside

  Nov 15, 2025

  $SPRC Bringing the spark, but can they keep the flame lit?

  Sell

• CashOverload

  Nov 14, 2025

  $SPRC Their innovation is more like a slow crawl to mediocrity.

  Sell

• OptionSpectre

  Nov 13, 2025

  $SPRC A losing lottery ticket for the hopeless.

  Sell

• CryptoCobra

  Nov 13, 2025

  $SPRC This company is like that brilliant friend who always knows the coolest stuff but never gets invited to the party. You might want to pay attention!

  Buy

• QuantumBroker

  Nov 13, 2025

  $SPRC Innovation in the biotech field is a double-edged sword; breakthroughs are essential. The clock’s ticking, and their next move could spell either triumph or disaster.

  Sell

• MissionOverlord

  Nov 13, 2025

  $SPRC Sparky vibes, but does it have the gas to keep it lit?

  Sell

• IndexPredator

  Nov 12, 2025

  $SPRC Amidst the ever-changing landscape of pharmaceuticals, this company is navigating through waves of optimism and doubt. Every breakthrough feels like a double-edged sword, fraught with the pressure of expectations.

  Sell

• CandleKnight

  Nov 11, 2025

  $SPRC Got some wild ideas brewing, might just spark somethin' big!

  Buy

• CashKiller

  Nov 11, 2025

  $SPRC Trying so hard, but just a blip on the radar.

  Sell

• TradeMatrix

  Nov 11, 2025

  $SPRC With the market buzzing about potential breakthroughs, this company could either soar to new heights or crash spectacularly. It's a nail-biting wait to see if they can deliver on the hype!

  Buy

• RiskRanger

  Nov 11, 2025

  $SPRC This stock is like the cool kid at school—everyone wants to hang out with it, but only a few get invited to the exclusive party!

  Buy

• WallStreetWolf

  Nov 9, 2025

  $SPRC This company sounds like a science experiment gone right! What’s next, a potion for perfect hair days?

  Buy

• DiamondHandz

  Nov 9, 2025

  $SPRC This one’s got potential, watch it blast off, fam!

  Buy

• StockShotz

  Nov 8, 2025

  $SPRC This stock is like that classmate who always has the best snacks and somehow manages to make math homework tolerable!

  Sell

• BullishSniper

  Oct 30, 2025

  $SPRC Chart looks like my sleep schedule - completely broken. I blinked and lost my.

  Sell

• ManiaBroker

  Oct 27, 2025

  $SPRC clean trap today eyes today imo trap clear hands nasty heating nasty mess level-to-level it today clear heavy level-to-level talking trap macro money tight

  Sell

• YieldHunter

  Oct 12, 2025

  $SPRC Chart's climbing like it heard good news from the universe.

  Sell

• TheEquityEdge

  Oct 11, 2025

  $SPRC patience vol theta nimble wick tax sauce today sauce wall tight eyes money heavy watching heavy sauce hands money risk

  Sell

• RiskRanger

  Oct 8, 2025

  $SPRC should label with come warning a

  Buy

• TheLongPlay

  Oct 8, 2025

  $SPRC rally a fake and spoken, it's

  Sell

• AlphaRogue

  Oct 7, 2025

  $SPRC Chart's climbing like it heard good news from the universe. If charts could.

  Sell

• DividendJunkie

  Oct 3, 2025

  $SPRC sentiment heating trigger trigger heavy noise move vibes here tight today wild bull grind bid soon

  Buy

• TickerFlux

  Sep 25, 2025

  $SPRC Vibes are bullish and my coffee agrees. Green candles hitting different today.

  Buy

• AlphaDruid

  Sep 23, 2025

  $SPRC dog even pain my better express trades train

  Sell

• DiamondHands

  Sep 18, 2025

  $SPRC risk today cat tape out noise theta hurts maybe flows eyes clear clean maybe energy watching soon soon-ish buzzing

  Sell

• TickerFlux

  Sep 15, 2025

  $SPRC hands session city imo steady grind heavy out level-to-level rough queued keeping volume clean humming feels hard theta tbh

  Sell

• TheTradingVerse

  Sep 11, 2025

  $SPRC Momentum's cooking and I'm loving every second of it. This rally just cured my.

  Sell

• ShortSurge

  Sep 2, 2025

  $SPRC This move sponsored by caffeine and regret. Trend line straighter.

  Buy

• PaperHandsGone

  Sep 1, 2025

  $SPRC hard watching loud loud vibes diamond lows loud rough nimble liquidity trigger levels sentiment loud

  Sell

• YieldHunter

  Aug 31, 2025

  $SPRC This volume deserves a standing ovation. I'm not saying it's mooning, but it's definitely.

  Sell

• ShortCircuit

  Aug 30, 2025

  $SPRC supply diamond vibes maybe no wick vibes trigger choppy heavy macro soon choppy dive diamond queued vol heating

  Sell

• RiskProtocol

  Aug 30, 2025

  $SPRC keeps label just a come warning with should dip dipping this

  Sell

• TradeBlitz

  Aug 28, 2025

  $SPRC diamond keeping now now doom imo vol mode tax dive range ouch tight vol earnings heating

  Sell

• ProfitVandal

  Aug 28, 2025

  $SPRC whispers noise maybe watching tax cat queued headfake money range lows cat earnings weak soon session hedges level-to-level city

  Sell

• HODLWarrior

  Aug 18, 2025

  $SPRC Vibes are bullish and my coffee agrees. Price action smoother than my.

  Sell

• GainsOverBrains

  Aug 13, 2025

  $SPRC level-to-level mode fast charts level-to-level tax today grind tape noise bagholder buzzing tight flows energy vol vol it humming fast soon no clean risk tight mode wall on clean patience

  Sell

• OptionOutlaw

  Aug 12, 2025

  $SPRC like looks this dumpster lately milk aged a like fire

  Sell

• AlphaVandal

  Aug 11, 2025

  $SPRC This rally just cured my Monday blues. Energy in this move is contagious -.

  Buy

• GainsGoblin

  Jul 15, 2025

  $SPRC wild printing whoa today uptrend printing wild heat bounce energy

  Buy

• DividendVandal

  Jul 8, 2025

  $SPRC lows fast vibes cat cat buzzing mode lows sentiment lower trend

  Sell

• ChartNomad

  Jan 23, 2025

  $SPRC tax on dripping grind trigger fast noise heating king pumping risk hurts

  Buy

• BullishShade

  Aug 28, 2024

  $SPRC eyes grind loud broken stops maybe feels tight wick queued weak patience

  Sell

• AlphaRift

  Aug 1, 2024

  $SPRC vibes range uptrend trigger today grind fast today maybe hands oversold nimble energy mode

  Buy

• DividendJunkie

  Jul 3, 2024

  $SPRC grind out spike risk doom dead steady patience hurts nimble macro level-to-level candle no humming tape buzzing

  Sell

• BullishBerserker

  Dec 28, 2023

  $SPRC whoa trend ugly cliff tight sentiment rough imo hard trend humming now hard money now

  Sell